785 mAZD0171 mediated LIF blockade in combination with chemotherapy and PD-L1 inhibition repolarizes macrophages and increases T cell infiltration via CX3CR1-CX3CL1 axis

• Scott Hammond,
• Robert Wilkinson,
• Michal Sulikowski,
• Jean-Martin Lapointe,
• Gozde Kar,
• Jim Eyles,
• Scott Hoffmann,
• Nadia Luheshi,
• Juliana Candido,
• Grace Opoku-Ansah,
• Fabien Garcon,
• Chelsea Gerada,
• Bairu Zhang,
• Rakesh Choudhary,
• Douglas C Palmer,
• Stewart Jones

Affiliations

Scott Hammond

3AstraZeneca, Gaithersburg, MD, USA

Robert Wilkinson

1AstraZeneca, Cambridge, Cambridgeshire, UK

Michal Sulikowski

5 Clinical Pharmacology & Safety Sciences, AstraZeneca PLC, Cambridge, Cambridgeshire, UK

Jean-Martin Lapointe

5 Clinical Pharmacology & Safety Sciences, AstraZeneca PLC, Cambridge, Cambridgeshire, UK

Gozde Kar

Oncology R&D, AstraZeneca, Cambridge, UK

Jim Eyles

Oncology R&D, Research and Early Development, AstraZeneca R&D, Cambridge, UK

Scott Hoffmann

1AstraZeneca, Cambridge, UK

Nadia Luheshi

2AstraZeneca, Cambridge, Cambridgeshire, UK

Juliana Candido

1AstraZeneca, Cambridge, Cambridgeshire, UK

Grace Opoku-Ansah

3AstraZeneca, Gaithersburg, MD, USA

Fabien Garcon

1AstraZeneca, Cambridge, Cambridgeshire, UK

Chelsea Gerada

1AstraZeneca, Cambridge, Cambridgeshire, UK

Bairu Zhang

1AstraZeneca, Cambridge, Cambridgeshire, UK

Rakesh Choudhary

1AstraZeneca, Cambridge, Cambridgeshire, UK

Douglas C Palmer

2AstraZeneca, Waltham, MA, USA

Stewart Jones

1AstraZeneca, Cambridge, Cambridgeshire, UK